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INTRODUCTION
Dysgerminoma is a malignant ovarian tumor beginning in premeiotic 
germ cells, with clinically aggressive behavior and good prognosis. Triple-X 
syndrome is characterized by an extra X chromosome due to a random error 
during cell division in sperm or egg formation and is not typically an inherited 
condition. Premature ovarian failure or ovarian abnormalities are sometimes 
found coincidentally. Associations between triple X syndrome and dysger-
minoma have never been investigated. 
CASE REPORT
A 22-year-old woman with Marfanoid habitus and an ovarian dysgermi-
noma (Fig.1) was admitted to the Department of Gynecology. The patient’s 
medical history showed borderline intellectual disability and clinical suspicion 
of Marfan syndrome (MFS) (Fig. 2) 
Surgical treatment was performed, and post-surgery, four cycles of bleo-
mycin, etoposide, cisplatin (BEP) chemotherapy. She is alive and well with no signs of 
recurrence 10 years after the completion of treatment.
MATERIAL AND METHODS
Cytogenetic studies were performed using conventional GTG–banding of lymphocyte 
metaphase chromosomes at a 550-band level. DNA was isolated from the peripheral blood 
leukocytes of the patient and of nine anonymous healthy female volunteers (reference 
control DNA). Array Comparative Genomic Hybridization (aCGH) analysis was performed. 
Genomic imbalances identified were verified in the Database of Genomic Variants (DGV; 
http://projects.tcag.ca/variation; last accessed December 2020). We searched ECARUCA 
[1], Decipher [2] and Medline/OMIM [3] for instances of patients with constitutional 
chromosomal aberrations at chromosome 4q26. 
RESULTS
The patient was diagnosed with triple-X syndrome by karyotyping: 47, XXX. Further 
aCGH analysis confirmed the chromosome analysis and identified interstitial deletion of 
about 1.1Mb at chromosome 4q26. 
Following the revised Ghent Marfan Syndrome Diagnostic Criteria (2010) [4], the 
patient having only skeletal features but no signs of other organ systems’ involvement, 
and a negative mutation evaluation of the FBN1 gene, diagnosis excluded MFS. Differ-
ential diagnosis identified Shprintzen-Goldberg syndrome [5] as the most likely alternative diagnosis.
Figure 1. Dysgerminoma. Uniform tumor cells surrounded 
by connective tissue stroma infiltrated by lymphocytes 
(H&E, ×20)
Figure 2. Clinical features of Marfanoid 
habitus (dolichocephaly, micrognathia, 
pectus carinatum, elongated extremities)
467
Karolina Kowalczyk et al., Late diagnosis and management of 46 XY complete gonadal dysgenesis in adulthood
www. journals.viamedica.pl/ginekologia_polska
DISCUSSION
Genetic studies confirmed diagnosis of the triple-X syndrome and revealed a novel interstitial deletion at chromosome 
4q26. The deletion spanned 1.1Mb, comprised of one gene protein coding: translocation associated membrane protein 1 like 
1 (TRAM1L1) of unknown function. 
The OMIM database provided no information on this gene mutation [3], nor is such reported in the Developmental Disorders 
Genotype-Phenotype Database [2]. The decipher haploinsufficiency score (HI index) was estimated as 85%, and accordingly, the gene 
is unlikely to exhibit haploinsufficiency [2]. The adjacent genomic regions were not found to be enriched in low copy repeat sequences 
or segmental duplications, nor possessing significant enhancer/silencer or promotor-associated histone marks (www.genome.ucsc.
edu). Therefore, it seems unlikely that the novel 4q26 deletion was responsible for the clinical features observed in the patient.
Among individuals with chromosome aberrations, a higher risk of germinal tumors has been found in cases of 45,X/46,XY 
mosaicism, resulting in active oncological prophylaxis in these patients. Associations between triple-X syndrome and ovarian tu-
mors have been rarely documented. Ovarian tumors have not been clinically linked to Shprintzen-Goldberg syndrome so far. 
However, further research on the cooccurrence of germ cell tumors and chromosomal abnormalities is necessary to identify risk 
factors of these relatively rare neoplasms. 
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